CO6400194A2 - Nuevas bencesulfonamidas como bloqueadores de canales de calcio - Google Patents

Nuevas bencesulfonamidas como bloqueadores de canales de calcio

Info

Publication number
CO6400194A2
CO6400194A2 CO11097206A CO11097206A CO6400194A2 CO 6400194 A2 CO6400194 A2 CO 6400194A2 CO 11097206 A CO11097206 A CO 11097206A CO 11097206 A CO11097206 A CO 11097206A CO 6400194 A2 CO6400194 A2 CO 6400194A2
Authority
CO
Colombia
Prior art keywords
formula
calcium channel
bencesulphonamids
new
channel blockers
Prior art date
Application number
CO11097206A
Other languages
English (en)
Inventor
Qingwei Zhang
Andrew O Stewart
Zhiren Xia
Michael F Jarvis
Victoria E Scott
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41796157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6400194(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO6400194A2 publication Critical patent/CO6400194A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)

Abstract

Inhibidores de canales de calcio que comprenden compuestos de fórmula (I), de fórmula (II), de fórmula (III) o de fórmula (IV),donde L1 es C(O) o S(O)2; uno de R1 y R2 es X, y el otro de R1 y R2 es Y; X es (i) o (ii); Y es -NRcAr1, -NRcAr2-Ar1, -NRcCH(Ar1)2, entre otros: R3, R4, R5 y R6 son en forma independiente entre sí hidrógeno, alcoxi, alquilo, o halógeno; R7 es -S(O)2Ar3, -C(O)Ar3, -S(O)2(CRaRb)pAr3, -C(O)(CRaRb)pAr3, entre otros y Rc es hidrógeno o alquilo. Además, la presente solicitud relaciona composiciones que comprenden dichos compuestos o sales farmacéuticamente aceptables de éstos, en combinación con uno o más vehículos farmacéuticamente aceptables y métodos para tratar afecciones y trastornos relacionados con los canales de calcio. Más particularmente, un método para tratar el dolor en un sujeto que lo necesita.
CO11097206A 2009-01-15 2011-08-02 Nuevas bencesulfonamidas como bloqueadores de canales de calcio CO6400194A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14489909P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
CO6400194A2 true CO6400194A2 (es) 2012-03-15

Family

ID=41796157

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11097206A CO6400194A2 (es) 2009-01-15 2011-08-02 Nuevas bencesulfonamidas como bloqueadores de canales de calcio

Country Status (22)

Country Link
US (3) US8101614B2 (es)
EP (1) EP2382191B1 (es)
JP (1) JP5619773B2 (es)
KR (1) KR20110110299A (es)
CN (1) CN102282131B (es)
AR (1) AR077440A1 (es)
AU (1) AU2010204753A1 (es)
BR (1) BRPI1005675A2 (es)
CA (1) CA2747752A1 (es)
CL (1) CL2011001714A1 (es)
CO (1) CO6400194A2 (es)
DO (1) DOP2011000217A (es)
ES (1) ES2527467T3 (es)
IL (1) IL213500A0 (es)
MX (1) MX337190B (es)
PE (1) PE20120126A1 (es)
RU (1) RU2011134052A (es)
SG (1) SG172308A1 (es)
TW (1) TW201028421A (es)
UY (1) UY32384A (es)
WO (1) WO2010083264A1 (es)
ZA (1) ZA201104715B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5501226B2 (ja) 2008-04-24 2014-05-21 Ｍｓｄ株式会社 アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
KR20140091522A (ko) * 2011-09-15 2014-07-21 타이페이 메디컬 유니이버시티 심부전증 또는 신경 손상을 치료하기 위한 인돌릴 및 인돌리닐 하이드록사메이트의 용도
US8648074B2 (en) 2011-09-29 2014-02-11 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
US8669255B2 (en) 2011-09-29 2014-03-11 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
WO2013103867A1 (en) 2012-01-05 2013-07-11 Abbvie Inc. Benzenesulfonamide derivative for use in the treatment of diabetic neuropathy
MX2015007460A (es) 2012-12-12 2015-09-04 Abbvie Inc Agentes para el tratamiento del dolor y usos de los mismos.
CN105873913B (zh) * 2013-09-10 2019-12-03 得克萨斯系统大学评议会 靶向截短的腺瘤性结肠息肉(apc)蛋白的治疗法
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
US10082496B2 (en) 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
FI3364993T3 (fi) 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi
AU2018221722B2 (en) 2017-02-15 2022-02-03 Cavion, Inc. Calcium channel inhibitors
EP3615521A4 (en) 2017-04-26 2021-02-17 Cavion, Inc. MEMORY AND COGNITION IMPROVEMENT, AND TREATMENT OF MEMORY AND COGNITIVE DISORDERS
EP3737382A1 (en) 2018-01-10 2020-11-18 Cura Therapeutics, LLC Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
CA3107145A1 (en) 2018-08-24 2020-02-27 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
US20220016095A1 (en) 2018-10-03 2022-01-20 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
CN114340670A (zh) 2019-07-11 2022-04-12 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
EP3997068A1 (en) * 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165508B1 (en) 1999-04-07 2004-06-23 The University of Virginia Patent Foundation Anticancer calcium channel blockers
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
EP1615698B1 (en) * 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
DE602004012083T2 (de) * 2003-04-15 2009-04-23 Astrazeneca Ab Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen
WO2006105127A2 (en) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2007052843A1 (ja) * 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
CA2666275A1 (en) * 2006-10-13 2008-04-17 Neuromed Pharmaceuticals Ltd. Cyclopropyl-piperazine compounds as calcium channel blockers
WO2008151184A1 (en) * 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
JP5501226B2 (ja) 2008-04-24 2014-05-21 Ｍｓｄ株式会社 アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers

Also Published As

Publication number Publication date
EP2382191B1 (en) 2014-11-12
AR077440A1 (es) 2011-08-31
JP2012515209A (ja) 2012-07-05
RU2011134052A (ru) 2013-02-20
KR20110110299A (ko) 2011-10-06
US8101614B2 (en) 2012-01-24
MX2011007496A (es) 2011-08-04
UY32384A (es) 2010-08-31
IL213500A0 (en) 2011-07-31
US8741899B2 (en) 2014-06-03
WO2010083264A1 (en) 2010-07-22
JP5619773B2 (ja) 2014-11-05
CL2011001714A1 (es) 2011-11-11
AU2010204753A1 (en) 2011-08-11
ZA201104715B (en) 2014-01-29
EP2382191A1 (en) 2011-11-02
PE20120126A1 (es) 2012-03-18
TW201028421A (en) 2010-08-01
MX337190B (es) 2016-02-16
CN102282131B (zh) 2015-08-26
SG172308A1 (en) 2011-07-28
ES2527467T3 (es) 2015-01-26
US8404719B2 (en) 2013-03-26
US20100197693A1 (en) 2010-08-05
US20120083499A1 (en) 2012-04-05
BRPI1005675A2 (pt) 2017-06-13
CA2747752A1 (en) 2010-07-22
CN102282131A (zh) 2011-12-14
DOP2011000217A (es) 2011-07-31
US20130210827A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
CO6400194A2 (es) Nuevas bencesulfonamidas como bloqueadores de canales de calcio
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
EA201490445A1 (ru) Циклопропанаминовое соединение
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
MX2015012028A (es) Inhibidores de la ruta de quinurenina.
ECSP11010880A (es) Compuestos orgánicos
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
PE20060583A1 (es) Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP11011427A (es) Piperidinas sustituidas como antagonistas de ccr3.
ECSP11011160A (es) Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
PE20151281A1 (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
UY31162A1 (es) Espiroindolinas como moduladores de receptores de quimioquinas
NI200900179A (es) Pirimidinil - piperazinas útiles como ligandos receptores de dopamina d3/d2.
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
EA201200866A1 (ru) Ингибиторы цистеиновых протеаз

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed